Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction

Inclusion Criteria: * aged 18-70 years * ischemic chest pain for \>30 min * admitted to hospital \<24 h after the onset of chest pain * electrocardiography showed ST segment elevation \>1 mm in two consecutive leads in the limb leads or \>2 mm in the precordial leads * they could be enrolled in the study \<72 h after successful revascularization Exclusion Criteria: * cardiogenic shock (defined as systolic blood pressure \<90 mmHg requiring intravenous pressors or intra-aortic balloon counterpulsation) * life-threatening arrhythmia * impossible conditions for cardiac catheterization * advanced renal or hepatic dysfunction * history of previous coronary artery bypass graft * history of hematologic disease * history of malignancy * major bleeding requiring blood transfusion * stroke or transient ischemic attack in the previous 6 months * structural abnormalities of the central nervous system (brain tumor, aneurysm, history of surgery) * traumatic injury after myocardial infarction * use of corticosteroids or antibiotics during the previous month * major surgical procedure in the previous 3 months * cardiopulmonary resuscitation for \>10 min within the previous 2 weeks * positive skin test for penicillin * positive result for viral markers (human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and Venereal Disease Research Laboratory (VDRL) test) * pregnancy, possible candidate for pregnancy or breastfeeding females * drug abusers * inappropriate patients to participate in the study according to the chief investigator